Form 4: Aytu BioPharma Director John Donofrio Jr. Receives Restricted Stock Grant

Director John Donofrio Jr. of Aytu BioPharma, Inc. was granted 1,500 common shares of restricted stock on November 6, 2024, vesting on the earlier of November 6, 2025, or the next annual stockholder meeting.

Summary

• John Donofrio Jr., a director of Aytu BioPharma, Inc., received a grant of 1,500 common shares of restricted stock on November 6, 2024.
• The shares vest on the earlier of November 6, 2025, or the date of the Issuer's next annual stockholder meeting.
• Following the transaction, Mr. Donofrio beneficially owns 3,762 common shares.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of stock could be seen as a positive sign of confidence in the company, but it's a routine event.

Positives

• The grant of restricted stock aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard practice for companies to grant stock to directors as part of their compensation package. It is common in the pharmaceutical industry to align the interests of management and shareholders.

Comparison to Industry Standards

• Stock grants to directors are a common practice across various industries, including pharmaceuticals, to incentivize performance and align interests with shareholders.
• The size of the grant can be compared to grants made to directors at similar-sized companies in the biotech sector to assess its relative value.

Stakeholder Impact

• The stock grant could have a slightly positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

Aytu BioPharma, Director, Restricted Stock, Beneficial Ownership, Form 4, Donofrio